Stay updated with breaking news from Jeff Settleman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Working to Outdo Cancer: A Multi-Modality Approach to Accelerating the Next Generation of Cancer Breakthroughs Friday, April 05, 2024 - 09:30am ...
NEW YORK CITY (dpa-AFX) - ORIC Pharmaceuticals Inc. (ORIC) said that it has reached a clinical development collaboration with Pfizer for a potential phase 2 study of ORIC-533 in multiple myeloma.ORIC
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Manuel Esteban / Shutterstock.com ORIC Pharmaceuticals (NASDAQ:ORIC)...
Though Gilead Sciences leads the group of companies developing immunotherapies that target the cancer protein CD47, Pfizer contends that molecules it is getting through the Trillium Therapeutics acquisition have safety and efficacy advantages that could make them the best in this emerging drug class.
Pfizer pours $25m into Vedanta's Phase II IBD study The pharma giant has invested in the clinical trial exploring the viability of Vedanta Biosciences’ VE202 inflammatory bowel disease treatment candidate. PureTech Health, a clinical-stage biotherapeutics firm, has announced its Vedanta Biosciences founded entity has landed a $25m (20.6 EUR) investment as part of the Pfizer Breakthrough Growth Initiative (PGBI). Vedanta plans to use the money to fund its Phase II study of VE202 to treat inflammatory bowel disease (IBD), scheduled to launch in 2021. A Vedanta spok...